Genome engineering firm Precision BioSciences has been strengthened patent protection on its core genetic modification technology.
The Research Triangle Park company announced today that the U.S. Patent and Trademark Office granted a patent related to Precision’s proprietary method of producing genetically modified cells using the company’s technology. Precision now says it has 13 issued genome engineering patents in the United States and one in Europe.
Precision’s proprietary Directed Nuclease Editor (DNE) technology enables the production of genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells. The technology has been used by companies in fields such as biopharmaceuticals, agricultural biotechnology and animal research.
